Mn Services Vermogensbeheer B.V. Buys 19,422 Shares of Merck & Co., Inc. $MRK

Key Points

• Mn Services Vermogensbeheer B.V. increased its Merck (MRK) stake by 2.0%, buying 19,422 shares to hold 974,621 shares worth about $102.59 million, which is roughly 0.6% of its portfolio and its 27th largest position.
• Analyst sentiment is broadly positive with an average rating of "Moderate Buy" and an average price target of $127.13, as several firms raised targets (e.g., BMO to $130/outperform, Goldman to $120/buy, RBC reaffirming $142).
• Significant insider selling occurred recently: CEO Robert M. Davis sold 47,434 shares and EVP Jennifer Zachary sold 121,573 shares, with insiders offloading 320,176 shares (~$38.3 million) in the past 90 days; insiders now own about 0.09% of the stock.

Mn Services Vermogensbeheer B.V. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 974,621 shares of the company's stock after purchasing an additional 19,422 shares during the period. Merck & Co., Inc. makes up approximately 0.6% of Mn Services Vermogensbeheer B.V.'s investment portfolio, making the stock its 27th largest holding. Mn Services Vermogensbeheer B.V.'s holdings in Merck & Co., Inc. were worth $102,589,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Chemung Canal Trust Co. boosted its position in shares of Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company's stock worth $6,407,000 after purchasing an additional 13,285 shares in the last quarter. First Pacific Financial increased its position in shares of Merck & Co., Inc. by 14.7% in the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company's stock valued at $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co increased its position in shares of Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company's stock valued at $17,444,000 after buying an additional 18,187 shares in the last quarter. Caxton Associates LLP raised its stake in Merck & Co., Inc. by 23.3% during the 2nd quarter. Caxton Associates LLP now owns 39,421 shares of the company's stock worth $3,121,000 after buying an additional 7,458 shares during the period. Finally, Coldstream Capital Management Inc. raised its stake in Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after buying an additional 13,940 shares during the period. Institutional investors own 76.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Morgan Stanley boosted their target price on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an "equal weight" rating in a research note on Friday, December 12th. The Goldman Sachs Group raised their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a "buy" rating in a research report on Tuesday, December 2nd. BMO Capital Markets upgraded Merck & Co., Inc. from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Cantor Fitzgerald increased their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $127.13.

Insider Buying and Selling at Merck & Co., Inc.

In related news, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total value of $5,599,109.36. Following the sale, the chief executive officer owned 443,602 shares of the company's stock, valued at approximately $52,362,780.08. This trade represents a 9.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock valued at $38,281,735 in the last 90 days. 0.09% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage cholesterol pill delivered large LDL cuts (≈64.6%) and met its head‑to‑head primary endpoint — a potential new blockbuster oral option for lowering “bad” cholesterol that could materially diversify revenue beyond oncology. Merck's drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) showed proof‑of‑concept in combined post‑ and precapillary pulmonary hypertension with HFpEF — opens a foothold in a hard heart‑failure segment and supports pipeline value. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” and a $142 price target — a sizable upside vs. current levels that can support investor confidence and buying interest. Benzinga coverage
• Neutral Sentiment: Retail and media attention (e.g., Jim Cramer’s “stay the course” call) has driven momentum into Merck stock over recent months; that attention can amplify swings but is not a fundamental catalyst. Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
• Neutral Sentiment: Industry reports list Merck as a major player in the growing cutaneous squamous cell carcinoma market — underscores long‑term TAM but not an immediate stock driver. Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion
• Neutral Sentiment: New FY2026 earnings estimates and coverage updates are circulating (Erste Group Bank note) — watch revisions for guidance confirmation versus management’s FY2026 EPS range. FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
• Negative Sentiment: Analysis flags an upcoming Keytruda patent cliff and Merck’s aggressive M&A push to refill the revenue gap — a strategic risk that could pressure sentiment if deal execution or integration falls short. Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $117.99 on Tuesday. The firm has a market cap of $291.71 billion, a PE ratio of 16.21, a PEG ratio of 2.31 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a fifty day moving average price of $116.83 and a 200 day moving average price of $102.29.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.